Sarepta Therapeutics (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sarepta Therapeutics" in English language version.

refsWebsite

Global rank English rank

5web.archive.org

1^st place

5bizjournals.com

407^th place

241^st place

3fda.gov

447^th place

338^th place

3sarepta.com

low place

2cnn.com

28^th place

26^th place

1iptonline.com

low place

1gene-tools.com

low place

1springer.com

274^th place

309^th place

1oregonlive.com

886^th place

517^th place

1xconomy.com

low place

6,978^th place

1abc6onyourside.com

low place

1marketwatch.com

1,303^rd place

808^th place

1fool.com

4,183^rd place

2,600^th place

1businesswire.com

615^th place

407^th place

1endpts.com

low place

1fiercepharma.com

low place

8,921^st place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1drugs.com

399^th place

333^rd place

1biocompounding.com

low place

1chemanager-online.com

low place

1reuters.com

49^th place

47^th place

1npr.org

92^nd place

72^nd place

1everylifefoundation.org

low place

abc6onyourside.com

Siefert, Kate (2023-05-09). "'It's transformational work,' Sarepta working on groundbreaking gene therapies in Columbus". WSYX. Retrieved 2023-10-05.

biocompounding.com

"A Biotech Growth Stock to Consider For Your Portfolio - Sarepta Therapeutics (NASDAQ: SRPT)". www.biocompounding.com. 2 October 2022.

bizjournals.com

portland.bizjournals.com

Moody, Robin J. (November 5, 2003). "AVI BioPharma's losses shrinking". Portland Business Journal. Retrieved 2009-10-24.
Moody, Robin J. (June 12, 2003). "AVI BioPharma stock reaches new 52-week high". Portland Business Journal. Retrieved 2009-10-24.
"AVI BioPharma loses $19.7M in Q2". Portland Business Journal. August 10, 2009. Retrieved 2009-10-24.
"AVI BioPharma gets $11.5M military contract". Portland Business Journal. October 5, 2009. Retrieved 2009-10-24.

bizjournals.com

"AVI BioPharma changes name, splits stock". Portland Business Journal. July 12, 2012. Retrieved 17 July 2012.

businesswire.com

"Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate". www.businesswire.com. 2023-01-05. Retrieved 2023-01-24.

chemanager-online.com

"Roche erwirbt Gentherapie von Sarepta Therapeutics | CHEManager". www.chemanager-online.com (in German). Retrieved 2024-09-20.

clinicaltrials.gov

"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy (DMD) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.

cnn.com

Tirrell, Meg (2023-06-22). "FDA approves $3.2 million gene therapy for rare muscular dystrophy in kids ages 4 and 5". CNN. Retrieved 2024-10-28.
Howard, Jacqueline (2024-06-20). "FDA expands approval of first gene therapy for rare form of muscular dystrophy". CNN. Retrieved 2024-10-28.

drugs.com

Sarepta's Marburg Drug Shows High Survival Rates After Intramuscular Delivery in Non-Human Primates. Marketwire, 4 March 2013.

endpts.com

Tarun, Shafiul Islam. "Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal". Endpoints News (in English, Bengali, and Hindi). Retrieved 2023-01-24.

everylifefoundation.org

"The Accelerated Approval Pathway and Rare Diseases" (PDF). EveryLife Foundation for Rare Diseases. Archived (PDF) from the original on 25 February 2022. Retrieved 26 July 2023.

fda.gov

Commissioner, Office of the (6 March 2019). "FDA grants accelerated approval to first drug for Duchenne muscular dystrophy". FDA.
U.S. Food and Drug Administration, Silver Springs, Maryland. News Release: FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation, December 12, 2019. Archived December 13, 2019, at the Wayback Machine
Mendoza, Melissa; Marks, Peter. "June 22, 2023 Approval Letter - ELEVIDYS". FDA. Archived from the original on 26 June 2023. Retrieved 26 July 2023.

fiercepharma.com

Keenan, Joseph (2023-01-05). "Catalent inks deal to manufacture Sarepta's DMD gene therapy". Fierce Pharma. Retrieved 2023-01-24.

fool.com

Renauer, Cory (2019-03-26). "Is Sarepta Therapeutics a Good Gene Therapy Stock to Buy Now? -". The Motley Fool. Retrieved 2019-05-21.

gene-tools.com

Summerton, J (2005). "Morpholino Antisense Oligos: Applications in Biopharmaceutical Research". Innovations in Pharmaceutical Technology. No. Sept. Retrieved 29 Oct 2012. | archiveurl = http://www.gene-tools.com/sites/default/files/Summerton2005_IPT.pdf

iptonline.com

Summerton, J (2005). "Morpholino Antisense Oligos: Applications in Biopharmaceutical Research". Innovations in Pharmaceutical Technology. No. Sept. Retrieved 29 Oct 2012. | archiveurl = http://www.gene-tools.com/sites/default/files/Summerton2005_IPT.pdf

marketwatch.com

Murphy, Mike (2017-06-28). "Sarepta Therapeutics names new CEO". MarketWatch. Retrieved 2024-10-28.

npr.org

Stein, Rob (22 June 2023). "Muscular dystrophy patients get first gene therapy". NPR. Archived from the original on 25 July 2023. Retrieved 26 July 2023.

oregonlive.com

DiMesio, Robbie (July 30, 2009). "AVI BioPharma moving HQ out of Oregon". The Oregonian. Retrieved 2009-10-24.

reuters.com

Leo, Leroy; Samal, Aditya (22 June 2023). "US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids". Reuters. Archived from the original on 29 June 2023. Retrieved 26 July 2023.

sarepta.com

investorrelations.sarepta.com

"FORM 10-K". UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Retrieved 2024-10-28.
Therapeutics, Sarepta. "Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45". Sarepta Therapeutics.

sarepta.com

"Our Pipeline, Building an industry-leading genetic medicine pipeline". Sarepta Therapeutics.

springer.com

Summerton, James E. (2017). "Invention and Early History of Morpholinos". In Moulton, Hong; Moulton, Jon (eds.). Morpholino Oligomers. Methods in Molecular Biology. Vol. 1565. New York, NY USA: Humana Press. ISBN 978-1-4939-6815-2.

web.archive.org

U.S. Food and Drug Administration, Silver Springs, Maryland. News Release: FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation, December 12, 2019. Archived December 13, 2019, at the Wayback Machine
Leo, Leroy; Samal, Aditya (22 June 2023). "US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids". Reuters. Archived from the original on 29 June 2023. Retrieved 26 July 2023.
Stein, Rob (22 June 2023). "Muscular dystrophy patients get first gene therapy". NPR. Archived from the original on 25 July 2023. Retrieved 26 July 2023.
Mendoza, Melissa; Marks, Peter. "June 22, 2023 Approval Letter - ELEVIDYS". FDA. Archived from the original on 26 June 2023. Retrieved 26 July 2023.
"The Accelerated Approval Pathway and Rare Diseases" (PDF). EveryLife Foundation for Rare Diseases. Archived (PDF) from the original on 25 February 2022. Retrieved 26 July 2023.

xconomy.com

Timmerman, Luke. Sarepta Moves From Seattle to Boston for the Talent. 7 September 2012.